Finance
Markets
No recent trading data. The last price we hold for ISRG is from Jun 3 (48 days ago). This symbol may be delisted, renamed, or halted — the figures below reflect its last active session, not the current market.

ISRG

stock Healthcare Medical Instruments & Supplies
Intuitive Surgical
$407.29 +4.99 (+1.24%) Delayed · quoted 47d ago
Healthy 62% Steady

What the indicators say

Bearish 0 of 5 trend signals bullish
Momentum · RSI 14 Leaning bearish
35
0oversold 30overbought 70100

RSI 35 — soft momentum, not yet oversold.

EMA 21 $431.09
Below
Near-term trend is down
SMA 50 $449.66
Below
Medium-term trend is down
SMA 200 $493.95
Below
Long-term trend is down
50 / 200-day
Death cross
50-day below the 200-day — bearish
Supertrend $442.58
Downtrend
Price is below the Supertrend band — bearish

A mechanical reading of the chart’s indicators — not investment advice.

Key statsas of Jun 3

The day open and close within the day's range
Low $399.46 High $407.85
Open
$407.29
+1.24%
Close
$407.29
+1.24%
52-week range where the price sits across its year
52w low $396.68 52w high $603.88
Current
$407.29
Prev close
$402.30
Volume 1.23× the 3-month average
0 avg 2× avg
Today
2.58M
3-mo avg
2.11M

Earningscalendar synced from Yahoo 57d ago

Most recent
Apr 2191 days ago
Next expected
Jul 21in 0 days

Recent earnings dates

  • Apr 21 91 days ago
  • Jan 22 180 days ago
  • Jan 14 188 days ago
  • Oct 21, 2025 273 days ago

Past earnings dates come from ISRG’s 8-K item 2.02 filings; the next date is Yahoo’s when available, otherwise estimated from the recent reporting cadence.

Fundamentalssynced from SEC 53d ago

Strong

Across the nine graded ratios (FY2025 balance-sheet figures, P/E on TTM through Mar 2026 earnings, against the latest price), ISRG’s fundamentals read as strong overall.

P/E ratio Weak
49.5x

At 49.5x, the price is steep relative to profit; the stock leans heavily on growth that has yet to arrive.

Share price divided by earnings per share: what you pay for each $1 of yearly profit. Roughly 15 to 25 is typical, above 40 is richly priced, and negative means the company is losing money.

Dividend yield Fair
0.00%

This company pays no dividend, common for firms reinvesting their profits back into growth.

The yearly dividend as a percent of the share price: the cash income each share pays out. Around 2 to 6% is healthy; above roughly 8% often signals the payout may be cut.

Profit margin Strong
28.4%

A 28.4% margin is strong; the company keeps a healthy slice of every revenue dollar.

The share of revenue left as profit once every cost is paid. Above 15% is strong; below 5% leaves little cushion against a bad year.

Return on equity Strong
16.0%

A 16.0% return on equity is strong; the company compounds owners' capital well.

Profit earned on each dollar of shareholder equity: how well the company compounds its owners' capital. Above 15% is strong.

Return on assets Strong
14.0%

A 14.0% return on assets is strong; the company squeezes good profit from its assets.

Profit earned on each dollar of assets: how efficiently the whole asset base is used. Above 8% is strong.

Debt-to-equity Strong
0.14

At 0.14, the company carries less in liabilities than in equity, a conservative balance sheet.

Total liabilities divided by shareholder equity: how heavily the company leans on borrowing. Below 1 is conservative; above 2 is highly leveraged.

Current ratio Strong
4.87

At 4.87, short-term assets comfortably cover short-term bills.

Current assets divided by current liabilities: whether short-term resources cover short-term bills. Above 1.5 is comfortable; below 1 is tight.

Revenue growth Strong
+20.5%

Revenue grew 20.5% from the prior year: strong top-line expansion.

Change in annual revenue from the prior fiscal year: whether the top line is expanding. Above 10% is strong growth; below 0 means revenue is shrinking.

Earnings growth Strong
+23.0%

Net income grew 23.0% from the prior year: strong profit expansion.

Change in annual net income from the prior fiscal year: whether profit is expanding. Above 10% is strong; below 0 means profit is falling.

Financialssynced from SEC 53d ago

FY2021FY2022FY2023FY2024FY2025
Revenue $5.7B$6.2B$7.1B$8.4B$10.1B
Net income $1.7B$1.3B$1.8B$2.3B$2.9B
Diluted EPS $4.66$3.65$5.03$6.42$7.87
Dividend / share
Total assets $13.6B$13.0B$15.4B$18.7B$20.5B
Total liabilities $1.6B$1.9B$2.0B$2.2B$2.5B
Shareholder equity $12.0B$11.1B$13.4B$16.4B$17.8B

Leadershipsynced from SEC 59d ago

  • Rosa David J. Chief Executive Officer (CEO) · Director
  • Samath Jamie EVP & CFO & Enterprise Technol
  • Brosius Mark EVP & Chief Mfg and Supply Cha
  • Charlton Henry L EVP & Chief Commercial and Mkt
  • Curet Myriam EVP & Chief Medical Officer
  • Jeddi Iman SVP & GM da Vinci Platforms &
  • Loeb Gary EVP & Chief Legal and Complian
  • Wadors Patricia L SVP Chief Human Resources Offi
  • Widman Fredrik VP Corporate Controller
  • Barratt Craig H Director
  • Beery Joseph C Director
  • Chew Lewis Director
  • Guthart Gary S Director
  • Johnson Amal M Director
  • Kolli Sreelakshmi Director
  • Ladd Amy L Director
  • Leonard Keith R Director
  • Nachtsheim Jami K Director
  • Reed Monica P Director

Officers and board are drawn from ISRG’s recent SEC ownership filings (Forms 3, 4 and 5).

Notable recent eventspast year

Large daily moves, new 6-month lows, year-over-year fundamentals swings, and reported leadership changes — pulled from the data this app already holds, never investment advice.

Recent SEC filingssynced from SEC 53d ago